ClinicalTrials.Veeva

Menu
O

Oregon Dermatology & Research Center | Portland, OR

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

VT-1161
NAFT-600
JNJ-77242113
Doxycycline
Tavaborole
Risankizumab
Terbinafine
Lutikizumab
Sofpironium Bromide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 13 total trials

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo an...

Active, not recruiting
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113 Matching Placebo
Locations recently updated

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. The purpose of this study is to evaluat...

Enrolling
Atopic Dermatitis
Drug: Placebo
Drug: Lutikizumab

Psoriasis is a long-term skin disease which causes red, itchy, scaly patches most commonly on the knees, elbows, scalp, and torso (chest, back, and a...

Active, not recruiting
Moderate Plaque Psoriasis
Drug: Risankizumab
Drug: Deucravacitinib

The key objective is to establish the efficacy, safety, tolerability, and pharmacokinetics of investigational drug Hallux Terbinafine Subungual Gel (...

Active, not recruiting
Onychomycosis of Toenail
Drug: Hallux Terbinafine Subungual Gel

Trial sponsors

Galderma logo
AbbVie logo
V
Bavarian Nordic logo
B
H
Janssen (J&J Innovative Medicine) logo
Merz Pharmaceuticals logo
Pfizer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems